Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope at Phoenix
Phoenix, Arizona, United States
Recruiting - Recruiting
- Not, yet, recruiting
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
James K. ManganNot, yet, recruiting - Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Patricia A. YoungNot, yet, recruiting - Not, yet, recruiting
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
Mark B. GeyerNot, yet, recruiting - Cleveland Clinic Foundation
Cleveland, Ohio, United States
Anjali S. AdvaniNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Oct 2025
- Primary completion
- 30 Mar 2029
- Completion
- 30 Mar 2029
- Last update posted
- 17 Mar 2026
- Registered enrollment
- 53
- Registry id
- NCT06918431
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.